Vertex Pharmaceuticals
VRTX
1,747 hedge funds and large institutions have $119B invested in Vertex Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 191 funds opening new positions, 704 increasing their positions, 616 reducing their positions, and 109 closing their positions.
75% more first-time investments, than exits
New positions opened: 191 | Existing positions closed: 109
14% more repeat investments, than reductions
Existing positions increased: 704 | Existing positions reduced: 616
13% more capital invested
Capital invested by funds: $106B → $119B (+$13.4B)
3% more funds holding
Funds holding: 1,695 → 1,747 (+52)
1.38% more ownership
Funds ownership: 93.56% → 94.94% (+1.4%)
9% more call options, than puts
Call options by funds: $853M | Put options by funds: $783M
29% less funds holding in top 10
Funds holding in top 10: 17 → 12 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.24B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$331M |
| 3 |
SG Americas Securities
New York
|
+$207M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$197M |
| 5 |
Millennium Management
New York
|
+$194M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$725M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$395M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$250M |
| 4 |
JP Morgan Chase
New York
|
-$228M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$191M |
VRTX Hedge Fund Activity: Q2 2026 in Review
1,747 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2026, worth a combined $119B — up 13% from $106B a quarter earlier.
Buyers outnumbered sellers: 191 funds opened new VRTX positions and 109 closed out — a net gain of 82 holders — while 704 added to existing stakes and 616 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.24B. The largest seller was Capital Research Global Investors, cutting an estimated $725M.
- 1,747 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2026, up from 1,695 in Q1 2026.
- Funds reported $119B of Vertex Pharmaceuticals stock for Q2 2026, up 13% quarter-over-quarter.
- 191 funds opened new Vertex Pharmaceuticals positions in Q2 2026 and 109 closed out, a net change of +82 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2026 was Franklin Resources, an estimated $1.24B added.
- The largest Vertex Pharmaceuticals seller in Q2 2026 was Capital Research Global Investors, an estimated $725M sold.
Based on aggregated 13F filings for Q2 2026.